Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PMA (premarket approval) review times continue to fall in the US

This article was originally published in Clinica

Executive Summary

The FDA has reduced further the time it takes to process applications to market medical devices in the US. In fiscal year 1998, which ended on September 31, the average review time for premarket approval applications (PMAs) from submission to approval fell to 12.4 months, a substantial 25% reduction on the 16.6 month average in 1997 and 50% less than the average of 25.9 months in 1996.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT082430

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel